ER migraine showdown: newer drug may beat standard treatment
NCT ID NCT06473597
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This study compares two fast-dissolving migraine tablets—rimegepant (Nurtec ODT) and rizatriptan (Maxalt MLT-ODT)—in adults coming to the emergency room with a migraine. The goal is to see which one provides better pain relief within 60 to 120 minutes. About 80 participants will be randomly assigned to receive one of the two medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Maimonides Medical Center
RECRUITINGBrooklyn, New York, 11219, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.